logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
9/14/2018 6:01:00 AM Alnylam Announces Publication In Circulation Of Exploratory Cardiac Endpoint Data From APOLLO Phase 3 Study Of Patisiran
8/30/2018 7:03:49 AM Alnylam Says EC Granted Marketing Authorization For ONPATTRO
8/21/2018 7:03:26 AM Alnylam Completes Enrollment In ENVISION Phase 3 Study Of Givosiran
8/15/2018 6:00:46 AM Karuna Appoints Steven Paul As CEO
8/13/2018 8:32:39 AM Arbutus’ LNP Licensee Alnylam Announces FDA Approval Of ONPATTRO For ATTR Amyloidosis
8/3/2018 7:02:07 AM Alnylam Says UK’s MHRA Grants Early Access To Patisiran
8/2/2018 8:01:53 AM Alnylam Pharma Q2 Loss Widens To $163.6 Mln Or $1.63/shr From $118.4 Mln Or $1.34/shr Last Year
7/27/2018 7:16:32 AM Alnylam Gets Positive CHMP Opinion For ONPATTRO For HATTR Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy
7/23/2018 7:00:39 AM Alnylam Presents New Analyses Of Clinical Results From APOLLO Phase 3 Study Of Patisiran
6/20/2018 7:01:28 AM Alnylam Pharma Appoints Masako Nakamura As SVP, Head Of Asia, And Jing Marantz As SVP, Head Of Medical Affairs